Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;49(12):4257-4263.
doi: 10.1007/s00261-024-04410-9. Epub 2024 Jun 20.

Percutaneous liver-directed therapies of intrahepatic cholangiocarcinoma

Brian Morse  1 , Melissa McGettigan  1 , Bela Kis  2
Affiliations
Review

Percutaneous liver-directed therapies of intrahepatic cholangiocarcinoma

Brian Morse et al. Abdom Radiol (NY). 2024 Dec.

Abstract

Cholangiocarcinoma is a hepatobiliary malignancy which can manifest anywhere along the biliary tree. Intrahepatic cholangiocarcinoma occurs in the liver within or beyond the second order bile ducts. The prognosis for patients with intrahepatic cholangiocarcinoma is poor, even when successfully resected there is a very high rate of local recurrence. The available systemic therapies are currently limited and have high rates of toxicity. Percutaneous and transarterial liver-directed therapies can be used to treat intrahepatic cholangiocarcinoma with results comparable to current standard of care systemic therapies in some circumstances. This manuscript will review these the techniques and efficacy of percutaneous and transarterial liver-directed therapies for intrahepatic cholangiocarcinoma.

Keywords: Chemoembolization; Intrahepatic cholangiocarcinoma; Liver-directed therapy; Microwave ablation; Radioembolization; Radiofrequency ablation.

PubMed Disclaimer

References

    1. M. C. Bragazzi, R. Venere, E. Ribichini, F. Covotta, V. Cardinale, and D. Alvaro, ‘Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment’, Digestive and Liver Disease. Elsevier B.V., Mar. 01, 2023. doi: https://doi.org/10.1016/j.dld.2023.08.052 . - DOI - PubMed
    1. R. Toth, P. J. Brindley, and J. Vaquero, ‘Enhancing the opportunities for cholangiocarcinoma precision therapy’, Gut. BMJ Publishing Group, 2024. doi: https://doi.org/10.1136/gutjnl-2023-331480 . - DOI - PubMed
    1. P. J. Brindley et al., ‘Cholangiocarcinoma’, Nature Reviews Disease Primers, vol. 7, no. 1. Nature Research, Dec. 01, 2021. doi: https://doi.org/10.1038/s41572-021-00300-2 . - DOI - PubMed - PMC
    1. G. Woodhead, S. Lee, L. Struycken, D. Goldberg, J. Hannallah, and S. Young, ‘Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma’, Life (Basel), vol. 14, no. 2, p. 217, Feb. 2024, doi: https://doi.org/10.3390/LIFE14020217 . - DOI - PubMed
    1. B. Kis et al., ‘Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma’, Cancer Control, vol. 24, no. 3. SAGE Publications Ltd, Sep. 06, 2017. doi: https://doi.org/10.1177/1073274817729244 . - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources